Lincocin (lincomycin) is indicated in infections caused by
gram-positive organisms which are sensitive to its action, particularly
streptococci and staphylococci. The drug has proven effective in eradicating
causative organisms in most of the common upper respiratory tract
infections, in septicemia, and in infections of the skin and adjoining
tissues.
Systemic therapy with LINCOCIN has been shown to be of
benefit in many animals with pustular dermatitis.
LINCOCIN has been demonstrated to be effective in the
treatment of staphylococcal infections resistant to other antibiotics and
sensitive to lincomycin. The drug may be administered in combination therapy
with other antimicrobial agents when indicated.
No serious hypersensitivity reactions have been reported and
many animals have received LINCOCIN repeatedly without developing evidence
of hypersensitivity.
Dogs, LINCOCIN has demonstrated
excellent efficacy in the treatment of upper respiratory infections and of
skin diseases, particularly those caused by staphylococcus and streptococcus
organisms. LINCOCIN has demonstrated efficacy even in some chronic
conditions of long standing and in infections which have resisted treatment
with other antibacterial agents.
Infections successfully treated with LINCOCIN include
pustular dermatitis, abscesses, infected wounds (including bite and fight
wounds), tonsillitis, laryngitis, metritis, and secondary bacterial
infections associated with the canine distemper-hepatitis complex.
Cats, LINCOCIN has demonstrated
efficacy in the treatment of localized infections, such as abscesses
following fight wounds, pneumonitis, and feline rhinotracheitis.
Success in the treatment of viral diseases must be
attributed to the control of susceptible secondary bacterial invaders rather
than to any effect of LINCOCIN on the virus.
Contraindications:
As with all drugs, the use of LINCOCIN products is
contraindicated in animals previously found to be hypersensitive to the
drug.
LINCOCIN should not be given to animals with known
preexisting monilial infections.
The following species are sensitive to the gastrointestinal
effects of lincomycin: rabbits, hamsters, guinea pigs and horses. Therefore,
the administration of LINCOCIN should be avoided in these species.
Adverse Reactions:
Loose stools occasionally have been observed in dogs and
cats on oral doses. Vomiting in cats has occasionally been reported
following oral administration.
Intramuscularly and intravenously, LINCOCIN products have
demonstrated excellent local tolerance with no reports of pain or
inflammation following injection.
Dosage and Administration
Oral: 10 mg per pound of body weight
every 12 hours or 7 mg per pound every 8 hours.
Intramuscular: 10 mg per pound of body
weight once a day or 5 mg per pound every 12 hours.
Intravenous: 5 to 10 mg per pound of
body weight one or two times per day diluted with 5 percent glucose in water
or normal saline and given as a drip infusion.
Treatment with LINCOCIN products may be continued for
periods as long as 12 days if clinical judgment indicates.
How Supplied:
LINCOCIN products for veterinary use are available in the
following dosage forms and strengths:
Tablets
100 mg: Each scored tablet contains
lincomycin hydrochloride equivalent to lincomycin, 100 mg; supplied in
bottles of 500.
200 mg: Each scored tablet contains
lincomycin hydrochloride equivalent to lincomycin, 200 mg; supplied in
bottles of 250.
500 mg: Each scored tablet contains
lincomycin hydrochloride equivalent to lincomycin, 500 mg; supplied in
bottles of 100.
AQuadrops
Each mL containing lincomycin hydrochloride equivalent to
lincomycin, 50 mg; preserved with methylparaben 0.075%, propylparaben
0.025%, and sorbic acid 0.1%. Supplied in 20 mL bottles with graduated
dropper.
Sterile Solution
Each mL containing lincomycin hydrochloride equivalent to
lincomycin, 100 mg.
Supplied in 20 mL vials.
Pharmacia & Upjohn
